[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.169.76. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
JAMA Oncology Clinical Evidence Synopsis
June 2018

Rituximab Maintenance Therapy After First-Line Induction Chemoimmunotherapy for Follicular Lymphoma

Author Affiliations
  • 1Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Phoenix, Arizona
JAMA Oncol. 2018;4(6):859-860. doi:10.1001/jamaoncol.2018.0111
Abstract

Clinical Question  Is rituximab maintenance therapy after first-line induction chemoimmunotherapy for follicular lymphoma associated with improved outcomes?

Bottom Line  Compared with observation, rituximab maintenance therapy prolongs progression-free survival without an improvement in overall survival or quality of life after first-line induction chemoimmunotherapy.

×